From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era-chemo-free or chemo-reform?
作者信息
Deng Haiyi, Zhou Chengzhi
机构信息
State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
出版信息
Transl Lung Cancer Res. 2021 Apr;10(4):1924-1927. doi: 10.21037/tlcr-21-179.
Abstract
摘要
相似文献
1
From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era-chemo-free or chemo-reform?从CheckMate 227到CheckMate 9LA：重新思考免疫治疗时代化疗的地位——无化疗还是化疗改革？
Transl Lung Cancer Res. 2021 Apr;10(4):1924-1927. doi: 10.21037/tlcr-21-179.
2
First line Immunotherapy for Non-Small Cell Lung Cancer.非小细胞肺癌的一线免疫疗法。
Pharmaceuticals (Basel). 2020 Nov 8;13(11):373. doi: 10.3390/ph13110373.
3
CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer.CheckMate 9LA研究：拓展非小细胞肺癌患者的治疗选择
Lancet Oncol. 2021 Feb;22(2):157-159. doi: 10.1016/S1470-2045(20)30701-4. Epub 2021 Jan 18.
4
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition.血清白细胞介素-6 和 C 反应蛋白与接受免疫检查点抑制治疗的黑色素瘤患者的生存相关。
J Immunother Cancer. 2020 Jun;8(1). doi: 10.1136/jitc-2020-000842. Epub 2020 Jun 23.
5
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.非小细胞肺癌患者一线纳武利尤单抗联合伊匹单抗加两个周期化疗（CheckMate 9LA）：一项国际、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
6
Adjuvant treatment combining cellular immunotherapy with chemotherapy improves the clinical outcome of patients with stage II/III gastric cancer.细胞免疫疗法联合化疗的辅助治疗可改善II/III期胃癌患者的临床结局。
Cancer Med. 2017 Jan;6(1):45-53. doi: 10.1002/cam4.942. Epub 2016 Oct 27.
7
Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting: what is the best approach?非小细胞肺癌一线治疗中的化疗和/或免疫检查点抑制剂：最佳治疗方法是什么？
Lung Cancer Manag. 2020 Feb 12;9(1):LMT22. doi: 10.2217/lmt-2019-0018.
8
The administration of adjuvant chemo(-immuno) therapy in the post ACOSOG-Z0011 era; a population based study.ACOSOG-Z0011 时代辅助化疗（免疫）治疗的应用；一项基于人群的研究。
Eur J Surg Oncol. 2018 Aug;44(8):1151-1156. doi: 10.1016/j.ejso.2018.03.003. Epub 2018 Mar 14.
9
Opportunities and challenges of active immunotherapy in dogs with B-cell lymphoma: a 5-year experience in two veterinary oncology centers.犬 B 细胞淋巴瘤主动免疫治疗的机遇与挑战：两家兽医肿瘤中心 5 年的经验。
J Immunother Cancer. 2019 Jun 7;7(1):146. doi: 10.1186/s40425-019-0624-y.
10
Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).抗 PD-1 单药治疗头颈部鳞状细胞癌患者的 III 期临床试验的对比分析（CheckMate 141 和 KEYNOTE 040）。
J Immunother Cancer. 2019 Apr 3;7(1):96. doi: 10.1186/s40425-019-0578-0.
引用本文的文献
1
International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease.肺癌合并慢性阻塞性肺疾病诊断与治疗的国际专家共识
Transl Lung Cancer Res. 2023 Aug 30;12(8):1661-1701. doi: 10.21037/tlcr-23-339. Epub 2023 Aug 24.
2
Lung cancer immunotherapy: progress, pitfalls, and promises.肺癌免疫疗法：进展、陷阱和前景。
Mol Cancer. 2023 Feb 21;22(1):40. doi: 10.1186/s12943-023-01740-y.
3
Efficacy and safety of maintenance immune checkpoint inhibitors with or without pemetrexed in advanced non-squamous non-small cell lung cancer: a retrospective study.维持性免疫检查点抑制剂联合或不联合培美曲塞治疗晚期非鳞状非小细胞肺癌的疗效和安全性：一项回顾性研究。
BMC Cancer. 2022 May 24;22(1):576. doi: 10.1186/s12885-022-09674-2.
4
Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI.表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）耐药后晚期非小细胞肺癌的免疫检查点抑制剂联合单药化疗
Front Oncol. 2021 Sep 20;11:700023. doi: 10.3389/fonc.2021.700023. eCollection 2021.
本文引用的文献
1
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.非小细胞肺癌患者一线纳武利尤单抗联合伊匹单抗加两个周期化疗（CheckMate 9LA）：一项国际、随机、开放标签、III 期临床试验。
Lancet Oncol. 2021 Feb;22(2):198-211. doi: 10.1016/S1470-2045(20)30641-0. Epub 2021 Jan 18.
2
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.阿替利珠单抗用于 PD-L1 选择的 NSCLC 患者的一线治疗。
N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346.
3
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors.免疫检查点抑制剂时代的化疗免疫刺激。
Nat Rev Clin Oncol. 2020 Dec;17(12):725-741. doi: 10.1038/s41571-020-0413-z. Epub 2020 Aug 5.
4
Advances in Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer: Targeted Therapy.局部晚期或转移性非小细胞肺癌治疗进展：靶向治疗。
Clin Chest Med. 2020 Jun;41(2):223-235. doi: 10.1016/j.ccm.2020.02.003.
5
Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.免疫检查点抑制剂联合化疗治疗非小细胞肺癌的分子基础和原理。
Drug Resist Updat. 2019 Sep;46:100644. doi: 10.1016/j.drup.2019.100644. Epub 2019 Sep 17.
6
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.纳武利尤单抗联合伊匹单抗治疗晚期非小细胞肺癌。
N Engl J Med. 2019 Nov 21;381(21):2020-2031. doi: 10.1056/NEJMoa1910231. Epub 2019 Sep 28.
7
The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy.培美曲塞通过叶酸代谢途径多效增强癌症免疫治疗效果。
Clin Cancer Res. 2019 Dec 1;25(23):7175-7188. doi: 10.1158/1078-0432.CCR-19-0433. Epub 2019 Aug 13.
8
Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.非小细胞肺癌：流行病学、筛查、诊断和治疗。
Mayo Clin Proc. 2019 Aug;94(8):1623-1640. doi: 10.1016/j.mayocp.2019.01.013.
9
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.阿替利珠单抗联合卡铂加白蛋白紫杉醇化疗与单纯化疗一线治疗转移性非鳞状非小细胞肺癌（IMpower130）：一项多中心、随机、开放标签、III 期临床试验。
Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.
10
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
Zotero 插件